12 Einträge gefunden

1. A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE)

   1. Schmidt, M
   2. Lübbe, K
   3. Decker, T
   4. Thill, M
   5. Bauer, L
   6. Müller, V
   7. Link, T

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
2. ViBiBa: Virtual BioBanking for the DETECT multicenter trial program - decentralized storage and processing

   1. Asperger, H
   2. Cieslik, J-P
   3. Alberter, B
   4. Köstler, C
   5. Polzer, B
   6. Müller, V
   7. Pantel, K

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
3. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program

   1. Müller, V
   2. Banys-Paluchowski, M
   3. Friedl, T W P
   4. Fasching, P A
   5. Schneeweiss, A
   6. Hartkopf, A
   7. Wallwiener, D

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
4. Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study

   1. Pivot, X
   2. Verma, S
   3. Fallowfield, L
   4. Müller, V
   5. Lichinitser, M
   6. Jenkins, V
   7. Sánchez Muñoz, A

   2017 - Forschungsinformationssystem des UKE
5. A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells

   1. Hvichia, G E
   2. Parveen, Z
   3. Wagner, C
   4. Janning, M
   5. Quidde, J
   6. Stein, Alexander
   7. Müller, V

   2016 - Forschungsinformationssystem des UKE
6. Subcutaneous Trastuzumab for HER2-positive Breast Cancer - Evidence and Practical Experience in 7 German Centers

   1. Jackisch, C
   2. Müller, V
   3. Dall, P
   4. Neumeister, R
   5. Park-Simon, T-W
   6. Ruf-Dördelmann, A
   7. Seiler, S

   2015 - Forschungsinformationssystem des UKE
7. Prognostic impact of transcription factor Fra-1 in ER-positive breast cancer: contribution to a metastatic phenotype through modulation of tumor cell adhesive properties

   1. Oliveira-Ferrer, Leticia
   2. Kürschner, M
   3. Labitzky, V
   4. Wicklein, D
   5. Müller, V
   6. Lüers, G
   7. Schumacher, U

   2015 - Forschungsinformationssystem des UKE
8. Circulating tumour cell-derived plastin3 is a novel marker for predicting long-term prognosis in patients with breast cancer

   1. Ueo, H
   2. Sugimachi, K
   3. Gorges, T M
   4. Bartkowiak, K
   5. Yokobori, T
   6. Müller, V
   7. Shinden, Y

   2015 - Forschungsinformationssystem des UKE
9. Subcutaneous Administration of Monoclonal Antibodies in Oncology

   1. Jackisch, C
   2. Müller, V
   3. Maintz, C
   4. Hell, S
   5. Ataseven, B

   2014 - Forschungsinformationssystem des UKE
10. Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

    1. Pivot, X
    2. Gligorov, J
    3. Müller, V
    4. Curigliano, G
    5. Knoop, A
    6. Verma, S
    7. Jenkins, V

    2014 - Forschungsinformationssystem des UKE
11. Circulating cell-free cancer-testis MAGE-A RNA, BORIS RNA, let-7b and miR-202 in the blood of patients with breast cancer and benign breast diseases

    1. Joosse, S A
    2. Müller, V
    3. Steinbach, B
    4. Pantel, K
    5. Schwarzenbach, H

    2014 - Forschungsinformationssystem des UKE
12. Sources of meaning in cancer patients - influences on global meaning, anxiety and depression in a longitudinal study

    1. Scheffold, K
    2. Mehnert, A
    3. Müller, V
    4. Koch-Gromus, Uwe
    5. Härter, M
    6. Vehling, S

    2014 - Forschungsinformationssystem des UKE